Jun Won Park
Seoul National University · Medicine
About the Lab
Professor Jun Won Park's research lab focuses on unraveling the molecular mechanisms underlying gastric cancer pathogenesis, with a particular emphasis on the roles of key tumor suppressors such as Smad4, p53, and E-cadherin in tumor progression and immune evasion. The lab develops and utilizes genetically engineered mouse models and patient-derived organoids to study gastric cancer stem cells, metastasis, and the tumor immune microenvironment. A central theme is understanding how loss of tumor suppressor pathways converges on β-catenin activation to drive metastatic spread and immune escape. The lab also aims to identify novel therapeutic targets and biomarkers for early detection and precision treatment of diffuse-type gastric cancer.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Incidence of PCP in patients with rheumatic diseases receiving prolonged, medium-dose steroids depends on the presence of risk factors. Prophylactic TMP-SMX may have greater benefit than potential risk in the high-risk subgroup.
Effective suppression of inflammation by TNFi treatment decreases radiographic progression in early AS.
A dose tapering strategy of TNFi is associated with more rapid radiographic progression in AS patients who have syndesmophytes at baseline.
Mild tapering of TNFi has efficacy comparable with that of the standard-dose treatment for ASDAS-ID achievement in patients with axSpA.
Although several clinical features were associated with detection failure, SF MSU crystal identification was critically dependent on the observer. Considering the impact on the treatment outcomes, implementation of a quality control program is essential.
The benefit associated with primary PJP prophylaxis outweighs the risk of severe AEs in patients with rheumatic diseases receiving rituximab and concomitant high-dose glucocorticoid treatment.
Our results showed that longitudinal serum urate levels were significantly reduced in men receiving ADT. This finding suggests that androgen could have an independent role in urate homeostasis.
New EUSTAR standardized mRSS training significantly enhanced mRSS accuracy, especially in participant with less previous experience in skin scoring.
Low-dose etanercept treatment after achieving clinical remission can be an alternative treatment option in terms of its comparable long-term efficacy and favourable safety in AS. More than 24 weeks of standard-dose treatment before dose reduction may be beneficial for longer drug survival in this strategy.
INH treatment to prevent TB might be effective in high-risk patients but has a risk of frequent ADRs, which limits its use in general practice in patients not at a high risk of developing TB.
Prophylactic TMP-SMX significantly reduced the risk of serious infections in patients with AAV, particularly during the first six months of induction therapy with RTX or CYC.
In patients with SLE exposed to prolonged medium-to-high-dose glucocorticoids, the 1-year incidence rate of BSI was significantly higher than previously reported in the general patients with SLE. Severe disease activity, and high-dose glucocorticoid treatment previously or at baseline increased the risk of BSI.
Tapering glucocorticoids with 12.5 mg/day of prednisone equivalent could be a reasonable timepoint to initiate the withdrawal of PJP prophylaxis in patients with rheumatic diseases.
Research Areas
Dive deeper into Jun Won Park's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.